Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 studyHagop M. Kantarjian, Susan O’Brien, Partow Kebriaei et al.|The Lancet Oncology|2012Cited by 411
Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 InhibitorsMohamed Shanavas, Vikas Gupta, Uday Popat et al.|Biology of Blood and Marrow Transplantation|2015Cited by 142